Jounce Therapeutics to Present at Upcoming Investor Conferences in March
February 23, 2021 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Participate in a Virtual Fireside Chat at Cowen 2020 IO Next Summit
November 09, 2020 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Second Quarter 2020 Financial Results
August 07, 2020 06:30 ET
|
Jounce Therapeutics, Inc.
- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 - - On track to initiate Phase 2 SELECT trial and Phase 1 trial for JTX-8064 in...
Jounce Therapeutics to Participate in a Fireside Chat at BTIG Virtual Biotechnology Conference 2020
August 04, 2020 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Participate in a Virtual Fireside Chat at the Raymond James Human Health Innovation Conference
June 10, 2020 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb
June 04, 2020 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports First Quarter 2020 Financial Results
May 06, 2020 06:30 ET
|
Jounce Therapeutics, Inc.
– Updating guidance on EMERGE and SELECT Phase 2 trials due to COVID-19 – – Announcing CCR8 as JTX-1811 target; new preclinical data to be presented at the AACR 2020 June virtual meeting – –...
Jounce Therapeutics to Present at Upcoming Investor Conferences in March
February 26, 2020 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 09, 2020 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Third Quarter 2019 Financial Results
November 07, 2019 06:30 ET
|
Jounce Therapeutics, Inc.
- New safety and preliminary efficacy data from JTX-4014 to be presented at the SITC 2019 Annual Meeting - - JTX-4014 data supports use as a combination agent for future studies - - 2019 cash...